Premium
Naltrexone/Bupropion extended release‐induced weight loss is independent of nausea in subjects without diabetes
Author(s) -
Hong K.,
Herrmann K.,
Dybala C.,
Halseth A. E.,
Lam H.,
Foreyt J. P.
Publication year - 2016
Publication title -
clinical obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.64
H-Index - 12
eISSN - 1758-8111
pISSN - 1758-8103
DOI - 10.1111/cob.12157
Subject(s) - nausea , medicine , weight loss , naltrexone , bupropion , diabetes mellitus , placebo , incidence (geometry) , comorbidity , gastroenterology , anesthesia , obesity , endocrinology , opioid , physics , receptor , alternative medicine , pathology , smoking cessation , optics
Summary Naltrexone/bupropion extended release (NB) is indicated as an adjunct to a reduced‐calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of ≥30 or ≥27 kg m −2 and ≥1 weight‐related comorbidity (e.g. hypertension, type 2 diabetes and dyslipidaemia). In phase 3 clinical studies, nausea occurred in significantly higher proportions of subjects randomized to NB vs. placebo (PBO). In this pooled analysis of three phase 3, 56‐week, PBO‐controlled studies, we characterized nausea and weight loss in NB‐ and PBO‐treated subjects without diabetes. Subjects receiving NB ( n = 1778) lost significantly more weight than those receiving PBO ( n = 1160). Weight change was not significantly different between subjects reporting and not reporting nausea in either treatment arm. Severity of nausea was mild to moderate in ≥95% of all cases. In the NB arm, the highest incidence of nausea onset (9%) was reported during week 1. The median duration of mild, moderate and severe nausea in subjects receiving NB was 14, 9 and 13 days, respectively. Our results demonstrate that nausea associated with NB is rarely severe, primarily occurs early in treatment and is not a contributor to weight loss.